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Abstract
In 2016, the European Commission launched the EU-ToxRisk research project to develop and promote animal-free approaches 
in toxicology. The 36 partners of this consortium used in vitro and in silico methods in the context of case studies (CSs). 
These CSs included both compounds with a highly defined target (e.g. mitochondrial respiratory chain inhibitors) as well as 
compounds with poorly defined molecular initiation events (e.g. short-chain branched carboxylic acids). The initial project 
focus was on developing a science-based strategy for read-across (RAx) as an animal-free approach in chemical risk assess-
ment. Moreover, seamless incorporation of new approach method (NAM) data into this process (= NAM-enhanced RAx) was 
explored. Here, the EU-ToxRisk consortium has collated its scientific and regulatory learnings from this particular project 
objective. For all CSs, a mechanistic hypothesis (in the form of an adverse outcome pathway) guided the safety evalua-
tion. ADME data were generated from NAMs and used for comprehensive physiological-based kinetic modelling. Quality 
assurance and data management were optimized in parallel. Scientific and Regulatory Advisory Boards played a vital role 
in assessing the practical applicability of the new approaches. In a next step, external stakeholders evaluated the useful-
ness of NAMs in the context of RAx CSs for regulatory acceptance. For instance, the CSs were included in the OECD CS 
portfolio for the Integrated Approach to Testing and Assessment project. Feedback from regulators and other stakeholders 
was collected at several stages. Future chemical safety science projects can draw from this experience to implement systems 
toxicology-guided, animal-free next-generation risk assessment.
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Introduction
A particular focus of EU-ToxRisk is on endpoints for 
repeated-dose (RDT) and developmental and reproductive 
toxicity (DART), and on providing guidance for practical 
implementation (Daneshian et al. 2016). This entails the 
implementation of NAM-based safety science into regula-
tory toxicology (Krebs et al. 2020b). The project initially 
focused on read-across (RAx) (Escher et al. 2019; Rovida 
et al. 2020a) and here we outline key outcomes and general 
learnings on the use of NAMs for RAx. This collection of 
outputs will facilitate new efforts in next-generation risk 
assessment (NGRA) (Dent et al. 2018; Dearfield et al. 2017; 
Cote et al. 2016; Krewski et al. 2014) and thus advance the 
field of safety assessment by more mechanistically driven 
and animal-free approaches (Suppl. Box 1). This report 
was assembled once an important project phase came to its 
conclusion. We will accentuate especially learnings on the 
regulatory implementation of new approaches. Moreover, 
we highlight some gaps and unresolved issues that will need 
future attention.
Incorporation of NAMs in read‑across 
approaches
The main activity of the project addressed the application of 
NAMs to support the most widely applied method of data-
gap filling: RAx. RAx may support safety assessment for 
the complex toxicological endpoints RDT and DART, yet it 
often fails to be accepted by regulatory agencies. Reasons 
for rejection often include the notion that associated uncer-
tainties are perceived as being too large. Classical RAx is 
based on structural similarity as the major argument, and 
there are many examples that chemical formula alone does 
not sufficiently predict toxicity. This uncertainty can be sub-
stantially reduced when NAMs demonstrate that source and 
target chemicals share similar biological and toxicokinetic 
profiles, providing justification for reading across source 
chemicals’ in vivo data.
The project hypothesis was that NAMs can reduce uncer-
tainty in traditional RAx (Fig. 1). For instance, they help 
characterize the biological properties of source and target 
compounds. NAMs can point out a specific molecular ini-
tiation event [e.g. receptor (ant)agonism], provide data on 
test compound hazard (i.e. expected types of adverse out-
comes), elucidate a mode of action (i.e. pathways and tar-
gets affected), or assess relative potencies of the observed 
effects. Also, the absence of a certain mechanism or effect 
can be demonstrated, as well as the relatively low potency 
for a certain testing endpoint. The EU-ToxRisk RAx testing 
framework demonstrated how NAMs can be integrated into 
practical RAx procedures (Escher et al. 2019).
If the AOP for a set of chemicals is known, NAM test-
ing can be designed along this mechanistic framework to 
explore molecular initiating events (MIEs) or key event (KE) 
responses. Targeted testing aims to generate mechanism-
related data for all grouped compounds, to either confirm 
(dis)similarity or observe a consistent trend. If no AOP is 
known, the battery of NAMs can be chosen in a way to cap-
ture as many as possible potential underlying mechanisms. 
NAMs can alternatively be used for broad untargeted test-
ing to either (1) generate a RAx hypothesis based on shared 
in vitro effects, or (2) to prove the absence of effects (up to 
concentrations corresponding or exceeding those obtained 
in humans under realistic exposure situations).
Besides resolving many conceptual uncertainties, 
NAM data, like any other type of experimental result, may 
Fig. 1  Reduction of RAx 
uncertainties by NAMs. The 
top box lists several uncertain-
ties that may weaken a RAx 
approach (e.g. uncertainty on 
the similarity of source and 
target, uncertainty on metabo-
lism, or uncertainty concerning 
the potency ratio of source 
and target). The bottom box 
indicates information that 
can be provided by NAMs to 
reduce uncertainty (e.g. data on 
potency ratios in key event (KE) 
or molecular initiation event 
(MIE) assays, or the identifica-
tion (ID) of relevant metabolites 
formed) 
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introduce their own uncertainty (assay variations, random 
noise, and congruence of different tests). This issue can be 
addressed by applying a structured and weighted descrip-
tion of uncertainties. This may use generalized Bayesian 
approaches or Dempster–Shafer decision theory (Dempster 
1967; Rathman et al. 2018; Shafer 1976), or it may use semi-
quantitative approaches based on expert judgment (Escher 
et al. 2019; Schultz et al. 2018). For instance, the Demp-
ster–Shafer approach allows for a fully quantitative com-
bination of various types of test data, taking into account 
the individual test performances/uncertainties, and to derive 
likelihoods of test data being correct. EU-ToxRisk puts sig-
nificant emphasis on diligent uncertainty descriptions and in 
taking initial steps towards uncertainty quantification. More 
resources will need to be put in place to apply these concepts 
in a more routine manner, and the science of uncertainty 
assessment is likely to become an important support disci-
pline of risk assessment.
Brief overview of case studies
Some of the project CSs were selected to test regulatory 
applicability of NAM-supported RAx. The design of a case 
study implied (1) the definition of a target chemical and a 
regulatory question, and (2) the delineation of data gaps and 
the approaches to fill them. A detailed overview and flow-
chart have been presented elsewhere (Graepel et al. 2019; 
Escher et al. 2019).
CSs were based on assemblies of structurally similar 
compounds to demonstrate how NAMs can be used to sub-
stantiate a RAx hypothesis. CSs always contained some 
chemical analogues with in vivo endpoint data, so that pre-
dictivity and accuracy of the NAM data could be verified. 
For the same reason, these CSs also included structurally 
similar compounds that did not exhibit a shared toxicologi-
cal effect patterns/AOPs in the in vivo data determining the 
RAx hypothesis. NAM data were subsequently used to better 
define the boundaries of the categories and to reduce uncer-
tainties. The description of the individual CSs is beyond the 
scope of this editorial and will be highlighted in individual 
publications. Here we specifically address the overall learn-
ings and impact of the CSs for RAx and their relevance for 
future next-generation risk assessment.
To illustrate the CS concept, we will describe a typi-
cal example: a CS focusing on the substance deguelin 
as a potential inducer of parkinsonian motor deficits. An 
AOP-based testing strategy was applied to support the 
RAx hypothesis. The AOP for inhibition of mitochondrial 
complex I of nigrostriatal neurons leading to parkinsonian 
motor deficits (Terron et al. 2018) was used to assess the 
biological similarity of two different rotenoids: rotenone 
(source compound, data-rich) and deguelin (target com-
pound, data-poor). For the source compound, there was 
compelling evidence for the induction of Parkinson’s-like 
disorders in experimental models, and also epidemiological 
evidence for similar effects in human (Ntzani et al. 2013). 
Various NAMs were selected to represent the MIE and KEs 
of the AOP. Both, in silico and in vitro test methods were 
applied. For instance, in silico structural modelling was used 
to identify the common pharmacophore that determines the 
binding to complex I, being the MIE of the AOP. To deter-
mine effects on the KEs, several in vitro methods were used 
to detect effects on mitochondrial respiratory activity (oxy-
gen consumption) and on proteostasis. High-content imag-
ing methods were applied for measuring damage to human 
dopaminergic neurons, and to compare the effects of the two 
compounds. Finally, PBK modelling was performed to com-
pare biokinetics and distribution of both compounds to the 
brain. The approach chosen in this case study demonstrated 
that an AOP-based testing strategy combining different test 
methods that cover the various KEs can be applied in sup-
porting chemical safety assessment within a NAM-based 
RAx framework.
Feedback by the Regulatory Advisory Board
Given the overall EU-ToxRisk objectives to provide solu-
tions for implementing NAMs in risk assessment, the NAM-
enhanced RAx case studies were presented and discussed 
on several occasions for feedback from the regulatory com-
munity. For this purpose, the project’s Scientific Advisory 
Board initiated close collaborations with regulators from 
national, European and international regulatory authori-
ties, including BfR and RIVM, ECHA, EFSA and EMA, 
and NIEHS, respectively. This cooperation resulted in an 
improved mutual understanding of the requirements and 
pitfalls of RAx approaches supported by NAMs, from a sci-
entific, academic, and regulatory perspective. The project’s 
Regulatory Advisory Board (representing the main agencies/
authorities) was set up in the course of the study as one of 
the first reactions to stakeholder feedback. It has since been 
key for the establishment of a reporting template for RAx 
cases. The extensive documentation and pre-validation of 
the EU-ToxRisk NAM toolbox is a step forward to increase 
the acceptability of regulatory dossiers based on NAM data. 
Overall regulatory learnings are summarized in Box 1.
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Box 1: Regulatory learnings based 
on the NAM‑based RAx framework assessment
I. Involve regulators from the start in the design of CSs 
so that they revolve around precisely phrased regulatory 
questions.
II. Meticulously define both regulatory context and 
hypothesis.
III. Provide a rationale for each step in the risk assess-
ment argument that regulators can follow and thus 
evaluate.
IV. Provide a clear learning scenario. Sharply define 
the situation before the RAx and before the use of NAMs. 
Evaluate the situation afterwards and provide transparent 
conclusions of what each method contributed.
V. Compare established risk assessment approaches 
with NAM-based RAx approaches and identify advan-
tages and shortcomings together with needs for future 
implementation training.
VI. Close interaction with the wider community of reg-
ulatory stakeholders is crucial to the establishment of the 
procedures. “Getting the science right” is very important, 
as is “getting the framing and reporting right” to match 
expectations and needs of the regulatory target audience.
Collected feedback from stakeholders 
and key opinion leaders on the EU‑ToxRisk 
NAM‑supported RAx framework
Following internal regulatory scrutiny, the project CSs and 
approaches were discussed in external forums. Learnings, 
achievements, and pitfalls of the approach were also ana-
lysed in detail in a dedicated workshop organized by EU-
ToxRisk in May 2019 in Espoo, Finland. Over 60 inter-
national experts from industry, academia, and regulatory 
authorities explored five scientifically advanced project 
case studies developed within EU-ToxRisk, the OECD/
Integrated Approach to Testing and Assessment (IATA) 
program, and NIHS Japan. The wide range of expertise and 
perspectives of the participants yielded valuable insights and 
answers to where and how NAMs can effectively support a 
RAx problem formulation, identify areas that contain data 
gaps, suggest how these gaps can be filled, and finally pro-
vide technical guidance on how those steps should be pre-
sented in a RAx regulatory dossier. Reports of three of the 
most mature EU-ToxRisk case studies, describing the RAx 
question, the approach taken (i.e. what NAM to select), the 
results obtained, and the conclusions derived, were further 
shared with the regulatory community for their review and 
feedback (Box 2).
Box 2: Learnings from stakeholder feedback
Scientific
I. Relevant aspects, such as xenobiotic metabolism and 
chemical or biological similarity considerations, should 
be addressed all at the same time to ensure a holistic 
coverage of potential contexts. Too much focus on one 
particular similarity context bears the danger of missing/
neglecting important effects and relevant context.
II. The regulatory question is important for determin-
ing the scope of the scientific approach. In some cases, 
all potential toxicities (or metabolites, or aspects of the 
chemical structure) may need to be considered. In other 
cases, it may be well acceptable to focus only on one 
relevant toxicity (e.g. neurotoxicity) or on one specific 
toxicophore.
III. Anchoring a toxicity hypothesis to an AOP is 
desirable. If not available, one may still perform a weight-
of-evidence approach using, for instance, a battery of 
NAM tests.
Regulatory
I. Qualitative expression of uncertainty is to be done in 
explicit categories (low/medium/high). Non-quantifiable 
uncertainties have to be made transparent. All underly-
ing uncertainties of the assessment need to be covered, 
including category formation, metabolism predictions, 
choice of NAMs, etc.
II. Focus and limit testing. The goal should be to do as 
much testing as needed to achieve sufficient confidence in 
a RAx justification, but not more than that.
Case study reviews by the OECD IATA Case 
Studies Project group
In parallel, these same three project case studies plus an 
additional one were also submitted to the OECD for review 
in its 5th Meeting of the IATA Case Studies Project under 
the remit of the Working Party on Hazard Assessment. 
The IATA Case Studies Project aims to assess the practical 
applicability of NAMs, as a part of the IATA framework, 
for different aspects of regulatory decision-making to build 
assessment experience (OECD 2015). The submitted EU-
ToxRisk project CSs underwent rigorous review by risk 
assessors from several countries, the OECD, and the Inter-
national Council on Animal Protection in OECD (ICAPO). 
The reviewing had a broad scope, assessing not only the 
data but also identifying where further guidance would be 
helpful, e.g. the regulatory relevance and the reporting. 
The OECD consideration document is set to be published 
adjacent to the CSs after their finalization based on com-
ments received. Final endorsement by the Working Party on 
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Hazard Assessment and the Joint Meeting members allows 
for their publication in September 2020. This represents a 
major milestone toward regulatory recognition of NAM-
based RAx (Box 3).
Box 3: Learnings from OECD feedback
Scientific
I. Provide argumentation for the selection of all com-
pounds and the rationale for their selection (or exclusion).
II. It is advantageous to quantitatively extrapolate 
NAM-based data to the (human) in vivo situation.
III. A good toxicity hypothesis (e.g. AOP-based) sup-
ported by NAM data can serve as justification for RAx.
IV. Inclusion of high-content data (e.g. toxicogenom-
ics) can increase overall confidence (e.g. of not missing 
important adverse effects).
Regulatory
I. Due to the lower level of validation of and experi-
ence with many NAMs in a regulatory context, it has to 
be ensured that recipients of RAx reports can understand 
all data provided, especially when methods are more 
complex and less well described in the literature.
II. Strengths and weaknesses, as well as rigorous 
uncertainty assessment, should be clearly addressed in 
the reporting.
EU‑ToxRisk advisory document 
on the proposed read‑across framework
From the three different case study reviewing phases, it 
became evident that RAx justifications should be presented 
as logically structured, coherent “stories”, along the “as 
comprehensive as needed, as concise as possible” principle.
Here the need for an advisory document that would be 
complementary to RAAF (ECHA 2017) and the OECD 
guidance document for in vitro test method descriptions 
(OECD 2014), addressing regulatory acceptance from the 
point of view of registrants of NAM-supported RAx dos-
siers. The Read-Across Advisory Report was structured 
back-to-back with the EU-ToxRisk overall RAx framework 
(Escher et al. 2019) and includes common learnings from 
the above discussion.
The advisory document targets the broader toxicology 
community with practical instructions on the applications of 
NAM-based RAx in different regulatory contexts, including 
all relevant collected feedback and endorsements on taken 
approaches. Its application will improve the submission 
quality of RAx cases by registrants and thereby increase suc-
cessful acceptance rates of non-animal approaches. For this 
purpose, an important component of the template already 
now is guidance on how to fill out the different sections of 
the risk assessment reporting submission document—espe-
cially with NAM data. A web-based graphical user interface 
(GUI) is being produced to facilitate its use.
The repository of NAMs available 
for NAM‑enhanced RAx
EU-ToxRisk started off with many NAMs available at part-
ner laboratories. They were selected and refined with the 
purpose of ensuring applicability in different regulatory 
contexts. Based on the initial toolbox, existing test meth-
ods were continuously refined to enhance their applicabil-
ity based on two parameters: test system complexity and 
test method throughput (Fig. 2). Simpler test systems were 
combined to obtain advanced complex test systems to better 
resemble the in vivo situation. These approaches include, 
for instance, the use of mixed cell cultures (Gutbier et al. 
2018), 3D organoids and neurospheres (Brull et al. 2020; 
Hiemstra et al. 2019; Kobolak et al. 2020) and microphysi-
ological systems (MPS), e.g. four-organ-chips developed to 
interconnect miniaturized human intestine, liver, brain and 
kidney equivalents (Ramme et al. 2019) and improved iPSC 
cell differentiation to hepatocytes (Boon et al. 2020). These 
advancements were fuelled by the establishment of novel 
differentiation protocols that produce high-quality cellular 
test systems (Ballester et al. 2019; Coll et al. 2018; Dreser 
et al. 2020; Gu et al. 2018; Rauch et al. 2018).
In parallel, the availability of advanced high-through-
put approaches was exploited to increase the applicability 
domains and throughput levels of the test methods. Screen-
ing transcriptomics data were provided from hepatic (Albre-
cht et al. 2019; Campos et al. 2020; Copple et al. 2019; 
Ramirez et al. 2018), renal (Limonciel et al. 2018a, b) and 
neuronal (Delp et  al. 2019) cell systems. High-content 
imaging was expanded to complex toxicological endpoints, 
such as DART (Dreser et al. 2020; Nyffeler et al. 2018) and 
systemic RDT with the establishment of novel fluorescent 
protein reporter cell lines (Bischoff et al. 2019; Schimming 
et al. 2019; Wink et al. 2018; Yang et al. 2020).
The toolbox was further enriched by novel in silico 
approaches, supporting and complementing in vitro cell-
based NAMs. An important area here was the extrapo-
lation of NAM concentrations to in vivo doses (IVIVE, 
PBPK) (Fisher et  al. 2019; Simeon et  al. 2020; Toma 
et al. 2018). Additionally, novel QSAR tools and machine 
learning approaches were put in place to assess chemical 
similarity among test compounds (Gadaleta et al. 2018a, 
b; Hemmerich et al. 2020; Luechtefeld et al. 2018; Toro-
pova et al. 2018; Toropov and Toropova 2017; Troger et al. 
2020) and to predict toxicological properties from their 
structure.
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Finally, the project defined new AOPs to seamlessly inte-
grate data generated by alternative methods or in vivo testing 
in a mechanistic and quantitative manner (Maertens et al. 
2018; Terron et al. 2018; Zgheib et al. 2019).
All this work contributed not only to the regulatory 
implementation of NAM-enhanced RAx, but also presented 
a scientific advance recognized by the academic community. 
This output is exemplified here by a selection of publica-
tions according to toxicological topics (Supp. Table 1), and 
high-ranking lists of papers in terms of citation and journal 
impact factor (Supp. Table 2; Supp. Table 3).
Knowledge infrastructure: sharing of data, 
test methods, results and knowledge
The scientific progress described above opens up new pos-
sibilities for reducing uncertainties associated with RAx and 
other risk assessment approaches. Irrespective, there was 
valuable feedback from regulatory specialists on the relative 
importance of high-end science vs the more basic quality 
control and documentation aspects. An important notion 
was that it is critical for regulators to quickly understand a 
new method; its information value, its purpose and its qual-
ity status. Similar considerations applied to data generated 
via NAMs, and it was enlightening to many contributing 
partners that the level of information sufficing for publica-
tion did not scale with regulatory requirements. The project 
team responded to this essential notion from the Regulatory 
Advisory Board by ensuring that all NAMs are described in 
a maximally transparent way to enable regulatory toxicolo-
gists to assess quality, reliability, applicability, and relevance 
of method outputs (Pamies et al. 2020; Bal-Price et al. 2018; 
Krebs et al. 2019). This approach was addressed by the use 
of comprehensive test method descriptions that also allow 
for the assessment of readiness levels of individual tools, 
combined with an efficient procedure for data upload (Krebs 
et al. 2020b). An efficient data management system was 
developed as a hub to transparently enable connecting meth-
ods to data, integrating data derived from different methods, 
and linking the integrated data to confirm or reject an overall 
testing hypothesis (like RAx).
Fig. 2  The EU-ToxRisk method toolbox. The EU-ToxRisk method 
toolbox includes test systems using cells from four major organ sys-
tems. In addition, models allowing readouts on DART have been 
included. The toolbox comprises both simpler cell models (2D, 
monoculture, etc.) and complex systems (3D, co-cultures, zebrafish 
embryos). The characteristics of each model determine their through-
put and their use at different stages of case studies. For each test 
system, various endpoints have been established, so that assays can 
be run to assess effects on cell viability in parallel with functional, 
biochemical, and toxicogenetics endpoints.  Figure adapted from the 
EU-ToxRisk project’s website (https ://www.eu-toxri sk.eu/page/media 
_items /test-metho ds8.php)
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In the context of a cross-system testing case study, 
detailed protocols for FAIR data handling were established, 
including the provision of sufficiently rich and transparent 
metadata explaining how data was produced. This includes 
the experimental setup and the various processing steps 
from raw to summary data such as benchmark concentration 
(Krebs et al. 2020a) or no-observed-adverse-effect-levels 
(NOAELs) used in risk assessment. EU-ToxRisk, together 
with its stakeholders, created test method descriptions and 
provided guidance on data processing (Krebs et al. 2018). 
A knowledge infrastructure was programmed that allows for 
efficient management of this information, using structured 
but still flexible input. The starting point is a detailed test 
method description including a standard operating procedure 
(SOP), and also more specific details on the validation status 
and relationship of the assay to AOPs.
The developed test method documentation (ToxTemp) 
covers mostly transparency and validation aspects. It was 
designed in alignment with the OECD Guidance Document 
211, which provides a template for “descriptions of non-
guideline in vitro methods”. The many types of essential 
information can be grouped into four sections: (1) the overall 
test method description, (2) the technical test procedure (as 
outlined in an SOP, e.g. defined labware, consumables and 
pipetting steps), (3) the characterization of test and reference 
materials/chemicals, and (4) all issues relating to data pro-
cessing and archiving. Finally, additional paragraphs address 
the test purpose, the test limitations (like information on its 
applicability), and the criteria to be used for interpreting 
test results. ToxTemp was endorsed by the project’s external 
advisory boards and over 30 experts from industry, regula-
tory bodies, and academia (Krebs et al. 2019). The public 
version of the ToxTemp method repository is available at 
https ://eutox risk.edelw eissc onnec t.com/publi c/). It is addi-
tionally used to provide metadata for the associated datasets 
as computer-readable annotations.
All EU-ToxRisk metadata linked to all project data out-
put will become available from the BioStudies database at 
the European Bioinformatics Institute (EBI) once the data 
have been publicly released (Sarkans et al. 2018). The EU-
ToxRisk knowledge-sharing platform accesses data from 
there and provides it to the consortium in a structured way 
for searching, browsing, visualization, and modelling pur-
poses and, ultimately, for decision-making in risk assessment 
as exemplified in project case studies (Fig. 3). Collecting test 
method information and metadata can be a time-consuming 
and error-prone task if done manually. Therefore, automated 
procedures were designed to collect data and metadata from 
experimental equipment and processing software and pro-
vide automated file validation tools to check data consist-
ency, complemented by human curation by multiple indi-
viduals as a final quality check (Box 4).
Box 4: Learnings on data management
I. Use harmonized templates for data and methods right 
from the project onset.
II. Invest time and resources into early training of 
researchers on data handling and management.
III. Provide and flexibly adapt data conversion and 
input tools.
Gaps and future requirements
Despite significant progress, there are still gaps that need 
to be addressed before standard risk assessment can be per-
formed entirely with animal-free methods. A comprehensive 
gap analysis would require an extensive vision document 
on the future of toxicology. This is beyond the scope of this 
short overview, but for an overview of past and current ideas, 
we refer to various visionary reports and documents (Cote 
et al. 2016; Hartung and Leist 2008; Khadka et al. 2020; 
Krewski et al. 2020; Leist et al. 2014, 2008; Lupu et al. 
2020; Sauer et al. 2015; Thomas et al. 2019, 2018).
Here, we outline nine key aspects that need further atten-
tion. This itemized summary may help in structuring work 
packages and defining strategies of future large risk assess-
ment projects (Fig. 4):
1. Method shop The width of in vitro and in silico NAMs—
and of strategies using them—is very large compared to 
traditional animal models. New concepts and business 
models are required to make broad panels of new models 
available to all stakeholders.
2. Human anchoring Method validation has traditionally 
relied on the correlation of NAM data with animal study 
data. Even though animal data was useful for the devel-
opment of NAMs, they also have shortcomings towards 
chronic/long-term human health consequences. There-
fore, the development and calibration of NAMs should 
also be anchored to human (patho)biology and not be 
calibrated exclusively by animal data.
3. Metabolism and transport More quantitative methods 
are required to predict the influence of metabolism and 
transport on the hazard of novel compounds.
4. Ab initio assessment Strategies need to be worked out to 
quickly arrive at a mechanistic hypothesis for the poten-
tial hazard of compounds with little or no prior safety 
information.
5. Non-toxicants A comprehensive strategy needs to be 
established on how to define compounds of low or no 
toxicity. This also requires measures for uncertainty. In 
particular, the risk of false-negative assessment needs to 
be evaluated.
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6. Immune system Both native and adaptive immune 
responses can be involved in toxicity (Benedetti et al. 
2013; Fasbender et al. 2020; Fredriksson et al. 2011, 
2014; Leist et al. 1997; Monshi et al. 2013). This notion 
needs further exploration to predict idiosyncratic reac-
tions and chronic health consequences for more suscep-
tible individuals.
7. Protection perspective Various past efforts attempted 
to substitute traditional hazard assessment with mod-
ern NAMs, following the concept that defined adverse 
Fig. 3  The EU-ToxRisk 
knowledge-sharing infrastruc-
ture. Data and metadata follow 
different flows to be processed 
and deposited into the respec-
tive data infrastructure. Raw 
data are processed and sum-
marized before being deposited 
into the Biostudies database 
at EMBL-EBI. Metadata are 
generated for each data set and 
deposited together into the 
knowledge-sharing database 
run by Edelweiss Connect. The 
coupled information is used for 
statistical model building and 
can be explored via visualiza-
tion tools. The collection of 
information allows for weight-
of-evidence-based decision-
making processes
Fig. 4  Elements of next-generation risk assessment (NGRA) frame-
work. NGRA should see the shift from mainly using NAMs for fill-
ing demarcated data gaps to a human-centric overall protection con-
cept underpinned by NAM-based hazard quantification. Immune 
responses need to be taken into account to predict idiosyncratic reac-
tions and chronic health consequences. To quantify risk and while 
accounting for associated uncertainties, NGRA will rely on integra-
tive systems toxicology-based modelling approaches, anchoring 
safety testing to in vivo human biology. Considering metabolism and 
transport early on will be key to arrive at hazard scenarios for new 
chemical compounds. To cater for the wider field of applied toxicol-
ogy, NGRA should be developed with both toxic and non-toxic, and 
both data-rich and data-poor compounds in mind
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events need to be identified and the subsequent animal-
based method to be substituted one-on-one by NAM(s). 
This strategy will fail for complex endpoints. It is even 
doubtful whether such an approach can cover all poten-
tial target organs and tissues in the human body, be it 
practically or at an acceptable cost. A future safety sci-
ence concept may require a more revolutionary approach 
that is not anchored to traditional adverse outcomes, but 
rather to the identification of safe concentrations. Stay-
ing below such concentrations would protect the popu-
lation from toxic effects by ensuring that no biological 
events linked to toxicity are activated. While some CSs 
of EU-ToxRisk started exploring this concept, future 
projects need to address this systematically.
8. Systems toxicology Points 3–6 need to be successfully 
incorporated into a comprehensive systems toxicology 
model, which will then eventually form the basis for 
point 9. This will involve outputs not only on concentra-
tion thresholds associated with hazard (and extrapola-
tions to respective doses/exposures), but also quantify 
the associated uncertainties.
9. Next-generation risk assessment Similar to the work 
of EU-ToxRisk on hazard assessment, the next step is 
to progress towards NGRA, using NAM-based hazard 
quantification in combination with defined exposure sce-
narios and exposure models.
An important future step to increase the impact of EU-
ToxRisk approaches will be the uptake of its tools and strate-
gies in upcoming initiatives (e.g. the Horizon Europe Part-
nership for the Assessment of Risk from Chemicals; PARC) 
and in collaboration with the private sector. Already some 
CSs in partnership with external industry stakeholders were 
initiated. Such joint CSs help to (1) inform strategic deci-
sions, (2) prioritize chemicals within a group, and (3) sup-
port the problem-solving process in investigative toxicology 
(Beilmann et al. 2019). Furthermore, the sustainability of the 
approaches will be supported by a commercialization plat-
form that consolidates NAMs and NAM data from different 
partner organizations, and use the integrated results in both 
safety assessment and investigative toxicology. In this con-
text, activities aiming to increase the international accept-
ance of the NAMs are crucial. This requires continued inter-
actions amongst all relevant stakeholders groups, including 
industry, regulatory agencies, academia, policy-makers, and 
NGOs (Busquet et al. 2020). For this reason, EU-ToxRisk 
provided many discussion platforms in the form of stake-
holder meetings, conference sessions, and closed workshops 
with regulators and parallel projects. Recent examples of 
such activities are the workshops on microphysiological 
systems and their regulatory application (Marx et al. 2020) 
and on international acceptance of read-across approaches 
(Rovida et al. 2020a, b) (Box 5).
Box 5: General learnings for future risk 
assessment projects:
I. Establish a Regulatory Advisory Board right from the 
onset (application phase).
II. Structure the project along CSs rather than work 
packages.
III. Anchor each CS to a strictly defined regulatory 
question.
IV. Use fit-for-purpose and well-structured risk assess-
ment reporting templates (compatible with regulatory 
requirements).
V. Ensure a strong emphasis on data management and 
establish consensus method description templates and 
data upload templates and provide a project data integra-
tion platform.
VI. Build and maintain networks with other toxicology 
programs. Maintain good personal relationships. Joint 
events and activities are necessary to make exchanges 
work, so reserve budget and resources to this end.
VII. For projects with a long runtime (≥ 5 years), 
allow for some re-organization possibilities and the re-
alignment of scientific goals as technologies progress and 
regulatory practice evolves.
VIII. Reserve budget for test method validation and 
sustainability measures.
IX. For all CSs, establish starting knowledge (pre-
registration); then evaluate the gain of knowledge after 
CS finalization.
X. For larger projects, finance and recruit a full-time 
scientific manager (in addition to administrative manage-
ment and overall project coordination).
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